University of Washington
This study investigates the changes in positron emission tomography (PET)/computed tomography (CT) imaging scans during chemoimmunotherapy and radiation therapy treatment in patients with stage IV non-small cell lung cancer. Analyzing changes in PET/CT imaging scans may help doctors assess and predict patterns of cancer response to chemoimmunotherapy and radiation therapy.
Patients undergo PET/CT scan within 4 weeks before starting standard of care chemoimmunotherapy and a second PET/CT scan within 5 days of the second chemoimmunotherapy cycle. Patients receiving standard of care radiation treatment undergo additional PET/CT scans within 4 weeks prior to radiation treatment and 1 month post-radiation treatment. Additionally, patients undergo blood sample collection on study. Patients may also undergo magnetic resonance imaging (MRI) as clinically indicated throughout the study.
Inclusion Criteria: * Histologically-confirmed or cytologically-confirmed metastatic NSCLC in patients who have not received chemotherapy or immunotherapy for their advanced disease (stage IV or recurrent, using the American Joint Committee on Cancer \[AJCC\]/Union for International Cancer Control \[UICC\] 8th edition for staging) * Evidence of stage IV disease on imaging by CT, PET/CT, or magnetic resonance imaging (MRI) * Plan to treat with a platinum doublet with a PD1 or PDL1 inhibitor * Adjuvant chemotherapy or concurrent chemoradiation for early stage disease does not count as prior the…
Undergo PET/CT scan
Undergo PET/CT scan
Receive standard of care chemotherapy
Receive standard of care immunotherapy
Undergo standard of care radiation therapy
Undergo blood sample collection
Undergo MRI
Arctuva estimate
Verify or correct the compensation shown for this listing.